首页|不同处方美沙拉秦(嗪)肠溶片中相关杂质的分析

不同处方美沙拉秦(嗪)肠溶片中相关杂质的分析

扫码查看
目的 考察国内 3个生产企业的 115批次美沙拉秦(嗪)肠溶片的杂质情况,并对其主要杂质进行初步定性及来源分析.方法 采用液相色谱法及液质联用法对3个生产企业的115批次样品进行相关杂质的定量及定性分析,并采用费休氏法对含特定杂质的样品进行水分的测定,考察该杂质与水分的相关性.结果 共检出4个主要杂质,杂质1、杂质2和杂质4为企业1样品的特有杂质,其中杂质 1、杂质2为处方中辅料与原料发生反应产生的杂质;杂质4 与水分相关,处方中的辅料可能会促进杂质 4 的产生.杂质 3 为欧洲药典中杂质G,3 个企业样品均有检出.结论 不同处方的美沙拉秦(嗪)肠溶片中的相关杂质差异较大,企业 1处方中的原辅料存在不相容的问题,建议企业1对处方进行变更.
Related impurities in different prescriptions of mesalazine enteric-coated tablets
Objective To determine the impurities in 115 batches of mesalazine enteric-coated tablets from 3 domestic manufacturers,and to conduct preliminary qualitative and source analysis of the main impurities.Methods The related impurities were quantitatively and qualitatively analyzed by liquid chromatography(LC)and LC-MS.The water content of samples containing specific impurities was determined by Fisher's method.The correlation between the impurities and water was studied.Results Totally 4 main impurities were detected.Impurities 1,2 and 4 were the specific impurities of the sample produced by enterprise 1,among which impurities 1 and 2 were the impurities produced by the reaction between the auxiliary materials and the raw materials in the prescription.Impurity 4 was a hydrolyzed impurity,and excipients in the prescription promoted the production of impurity 4.Impurity 3 was impurity G in the European Pharmacopoeia,which was detected in all samples from 3 companies.Conclusion The related impurities in mesalazine enteric-coated tablets in different prescriptions vary,and the raw materials in the prescription of enterprise 1 are incompatible,so enterprise 1 should modify related prescription.

mesalazine enteric-coated tabletprescriptionimpuritycompatibility of raw and auxiliary material

吴琦琦、刘轶、周明、李帅、李晓燕、刘雁鸣、文亮

展开 >

湖南省药品检验检测研究院,长沙 410001

美沙拉秦(嗪)肠溶片 处方 杂质 原辅料相容性

湖南省自然科学基金科药联合基金

2021JJ80041

2024

中南药学
湖南省药学会

中南药学

CSTPCD
影响因子:0.736
ISSN:1672-2981
年,卷(期):2024.22(2)
  • 7